| +0.02 / +0.37%|
The 11 analysts offering 12-month price forecasts for Idenix Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 6.00 and a low estimate of 2.00. The median estimate represents a -26.06% decrease from the last price of 5.41.
The current consensus among 14 polled investment analysts is to Hold stock in Idenix Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.